Apellis Pharmaceuticals, Inc. — Director's Dealing 2021

Jul 22, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2021-07-21

Reporting Person: DeLong Mark Jeffrey (Senior Vice President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-21	Common Stock	M	1000	$15.52	Acquired	10490	Direct
2021-07-21	Common Stock	S	1000	$65.00	Disposed	9490	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-21	Stock Option (Right to Buy)	$15.52	M	1000	Disposed	2028-02-04	Common Stock (1000)	Direct

Footnotes

F1: This is a scheduled exercise from an established 10B5-1 trading plan.

F2: This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant date, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.